Elevated expression of COX-2—associated with progressive tumor growth and resistance [8]—may have accounted for the increased resistance to DEA treatment of 4T1 TNBC cells compared to the HR+ MCF-7 cells. This evidence concerns the gene PTGS2 and neoplasm.